Three-Pronged attack tested to stop aggressive head and neck cancer
NCT ID NCT00875849
Summary
This study tested a combination treatment to prevent cancer from coming back in patients with high-risk head and neck cancer who had already undergone surgery. It combined radiation therapy, a standard chemotherapy drug (cisplatin), and a newer targeted drug (cetuximab). The main goal was to see if this intensive approach could keep patients cancer-free for at least two years after their surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
Conditions
Explore the condition pages connected to this study.